CADTH Canadian Drug Expert Committee recommendation. Safinamide (Onstryv -- Valeo Pharma Inc.) : indication: for add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson's disease (PD) in patients experiencing "OFF" episodes while on a stable dose of levodopa. Safinamide has not been shown to be effective as monotherapy for the treatment of PD.

CADTH Canadian Drug Expert Committee recommendation. indication: for add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson's disease (PD) in patients experiencing "OFF" episodes while on a stable dose of levodopa. Safinamide has not been shown to be effective as monotherapy for the treatment of PD. Safinamide (Onstryv -- Valeo Pharma Inc.) :

Show other versions (2)

The CADTH Canadian Drug Expert Committee (CDEC) recommends that safinamide should not be reimbursed as add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic PD in patients experiencing "OFF" episodes while on a stable dose of levodopa...

Full description

Saved in:
Bibliographic Details
Online Access: Full text
Format: Electronic eBook
Language:English
Published: Ottawa (ON) : CADTH, 2020
Edition:Version: 1.0.
Series:Common drug review clinical review report.
Subjects:
Parkinson Disease > drug therapy.
Alanine > therapeutic use.
Monoamine Oxidase Inhibitors > therapeutic use.
Antiparkinson Agents > therapeutic use.
Drug Therapy, Combination.
Insurance, Health, Reimbursement.
Canada.

Internet

Full text

Similar Items